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Abstract: Amphibian skin is a rich source of natural compounds with diverse antimicrobial and
immune defense properties. Our previous studies showed that the frog skin secretions obtained
by skin micro-organs from various species of Colombian anurans have antimicrobial activities
against bacteria and viruses. We purified for the first time two antimicrobial peptides from the
skin micro-organs of the Orinoco lime treefrog (Sphaenorhynchus lacteus) that correspond to Buforin
II (BF2) and Frenatin 2.3S (F2.3S). Here, we have synthesized the two peptides and tested them
against Gram-negative and Gram-positive bacteria, observing an effective bactericidal activity at
micromolar concentrations. Evaluation of BF2 and F2.3S membrane destabilization activity on
bacterial cell cultures and synthetic lipid bilayers reveals a distinct membrane interaction mechanism.
BF2 agglutinates E. coli cells and synthetic vesicles, whereas F2.3S shows a high depolarization and
membrane destabilization activities. Interestingly, we found that F2.3S is able to internalize within
bacterial cells and can bind nucleic acids, as previously reported for BF2. Moreover, bacterial exposure
to both peptides alters the expression profile of genes related to stress and resistance response. Overall,
these results show the multifaceted mechanism of action of both antimicrobial peptides that can
provide alternative tools in the fight against bacterial resistance.
Keywords: antibacterial activity; antimicrobial peptides; bacterial agglutination; buforin II; DNA
binding; frenatin 2.3S; frog skin secretions; membrane translocation; membrane leakage
1. Introduction
The alarming increase in the frequency of bacterial resistance to conventional antibiotics
during the last decade is nowadays one of the main global health concerns. The search for novel
antimicrobial drugs is a top priority for the World Health Organization (WHO). In this context, the host
defense peptides (HDP) or antimicrobial peptides (AMPs) have attracted particular interest from
the pharmaceutical industry. AMPs are predominantly cationic and contain a high percentage of
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hydrophobic residues. These features confer structural characteristics to the peptides that define
their biological activity and mechanisms of action, as well as represent a basis of new useful natural
antibiotics for pharmaceutical applications [1–3]. Overall, two main general mechanisms have been
described for accomplishing their antimicrobial activity. In brief, the first is involved in bacterial
membrane disruption and the second targets intracellular components such as nucleic acids following
the peptide internalization [4].
AMPs are often truncated versions of larger proteins within the cell. For example, histones
are proteins known for their function in the cell nucleus; nevertheless, they also can be found in
the cytoplasm, and the fragments of these proteins have been identified in frog skin secretions.
The proteolytic fragments were named histone-derived peptides and reported to display antimicrobial
and inflammatory properties [5]. One of the most studied histone derived peptides families are buforins
(Figure 1). Buforins are released by histone H2A proteolytic cleavage, together with other peptides,
such as parasins and hipposins. Within the buforin family the buforin II peptide (BF2), derived
from buforin I cleavage, displays a prominent antimicrobial activity and has attracted particular
interest. BF2 was first isolated from the stomach secretion of Bufo bufo gargarizans [6]; the AMP has
a primary sequence of 21 amino acids that adopts a helix-hinge-helix structure in a membrane mimic
environment (Figure 2) [7]. BF2 antibacterial activity has been reported against both Gram-positive
and Gram-negative bacteria. BF2 kills bacteria by entering the cells in a non-lytic manner and binding
to nucleic acids [8]. Interestingly, BF2 membrane translocation is independent of any cellular receptor
and the peptide can readily enter both bacterial cells and liposomes [9,10]. Previous studies have
shown the important role of proline in the ability of the peptide to translocate across the bacterial
membrane by the formation of transient toroidal pores [11–14]. Furthermore, some studies have shown
that buforin can act synergistically with other antibiotics such as cefazolin, thereby increasing the
antibacterial action and its activity against biofilms [12,15].
On the other hand, the AMP frenatin family was first described in the skin secretions from
the Australian frog Litoria infrafrenata [16]. Four frenatin peptides were identified as antimicrobial
active peptides with an unrelated primary structure to previous reported amphibian AMPs [16].
The novel treefrog peptides attracted the researcher interest because of their similarity with mammalian
peptides. Interestingly, later studies reported immunomodulatory and antitumoral properties for
frenatins [17,18]. Three frenatin sequences have been identified in Sphaenorhynchus lacteus (Figure 1).
The peptides are 16 to 17 amino acid long and share a high sequence identity, showing punctual
variations at the C-terminus. In particular, frenatin F2.3S was identified in our laboratory from
in vitro skin micro-organs (SMOs) of S. lacteus and shares low sequence identity with previously
described frenatins 1 and 3 [19,20], such as frenatin 1 from L. infrafrenata and Frenatin 2D from
Discoglossus sardus [16,21]. In contrast, frenatin 2.1S, 2.2S and 2.3S from S. lacteus conform a highly
homologous group with reported antimicrobial activity against both Gram-positive and Gram-negative
bacteria, including reference species and clinical strains [16,22]. Moreover, our group found that
F2.3S has the capacity to protect cells from yellow fever virus infection [19]; a property that might
be related to the immunomodulatory properties reported for the peptides of frenatin family [18].
The immunomodulatory activity was reported especially for frenatin 2.1 due to its capacity to
differentially stimulate macrophages in order to produce pro-inflammatory (TNFα, IL-23, IL-6) and
anti-inflammatory (IL-10) cytokines in mononuclear cells of mouse peritoneum and spleen [23]. In spite
of the previous studies about the antimicrobial and immunomodulatory activities of frenatins [19],
the mechanism of action of F2.3S remains unknown.
Frogs and toads have developed under evolutionary selective pressure a successful strategy for
surviving in microbe-laden hostile environments, which relies heavily on the secretion of chemical
cocktails of AMPs from specialized granular skin glands [24]. Therefore, the skin secretions of
amphibians work as a biological barrier against infection and are an extensive source of promissory
AMPs. Several studies have described hundreds of these peptides and their biological activities,
including antimicrobial activity, immunomodulation, chemotaxis, and cytotoxicity. Our research group
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has focused on the search of AMPs among the compounds secreted by common species of anurans
widely distributed in Colombia. In this context, the Orinoco lime treefrog (S. lacteus), belonging to the
Hylidae family, was considered as an attractive specie for our studies. The AMPs secreted by S. lacteus
frog SMOs were identified and characterized. Within the purified mixture two highly active peptides
caught our attention: BF2, showing the same primary sequence that the BF2 isolated from Bufo bufo
gargarizans stomach tissue, and a peptide belonging to the frenatin family, named frenatin 2.3S (F2.3S).
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Figure 2. Helical wheel projections of BF2 (A) and F2.3S (B). Cationic residues are highlighted in blue, 
uncharged residues in grey, polar residues in purple, nonpolar residues in yellow, polar/uncharged 
residues in pink and anionic residues in red. N-terminal and C-terminal domains are indicated with 
N and C letters respectively. The directions of hydrophobic moments of the peptides are denoted by the 
arrows in the middle of the wheels. Drawn by HeliQuest (available online: http://heliquest.ipmc.cnrs.fr/). 
BF2 secondary structure comprises a distorted-helix between residues 7–11 and a regular α-helix 
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The present study describes the characterization of BF2 and F2.3S peptides identified in SMOs of
S. lacteus and analyzes their antimicrobial activity against Gram-positive and Gram-negative species,
their action on membrane models and their potential intracellular targets. Our results highlight that
the two peptides are multifaceted molecules that can cover broad strategies to act against bacterial
pathogens. Both peptides show a combined membrane destabilization and intracellular mechanism of
action. Our results support the use of frog skin secretions as a rich source of multifaceted peptides to
develop alternative antimicrobial agents.
2. Results
2.1. Synthesis and Characterization of Physicochemical Properties of BF2 and F2.3S Peptides
In this study we have identified and evaluated BF2 and F2.3S peptides secreted by the granular
glands of S. lacteus skin. Previous studies identified the gene precursors of BF2 and F2.3S composed of
a signal peptide followed by an acidic spacer peptide, which is flanked by typical Lys/Arg amino acids.
The protein expression was confirmed by proteomic analysis of the secretions obtained from the SMOs
culture of S. lacteus [25]. Here, both peptides were synthesized according to the sequences identified in
previous studies [19,25]. The sequence alignment of the primary structure of the peptides buforins I
and II and Parasin I with a fragment of histone H2A shows that the peptides contain almost identical
sequences to the parental histone H2A, only differing in their size and region location (Figure 1).
On the other hand, the amino acid alignment of frenatins derived from S. lacteus (frenatins 2.1, 2.2 and
2.3) shows identities close to a 100% between them. Differences among S. lacteus frenatin 2 members
are only observed at the C-terminus, where frenatin 2.3 has an additional Gly residue. On the other
hand, frenatin 2, frenatin 1.1 (L. infrafrenata) and frenatin 2D (D. sardus) have much lower identity
percentages in comparison with F2.3S: 58%, 54% and 36% respectively.
The BF2 and F2.3S peptides primary structures were analyzed to identify their physicochemical
properties, stability and interactions in silico. Prediction of the peptide secondary structures using
the Antimicrobial Peptide Database (APD) and the PSIPRED protein sequence analysis servers
indicated the tendency for α-helix structuration of both peptides (Figure 2 and Figure S1) [26,27].
Noteworthy, a previous work by NMR reported that BF2 in water adopts a random structure, while in
water:trifluoroetanol (1:1) the peptide adopts a distorted helix spanning from residues Gly7 to Pro11
and a regular α-helix from Val12 to Arg20, as predicted by the PSIPRED program (Figure S1A) [7].
On the other hand, the PSIPRED server predicts for F2.3S a central α-helix spanning from Val3 to Leu15
residues (Figure S1B). The main physicochemical features of both peptides are summarized in Table 1.
Table 1. In silico physicochemical properties of the BF2 and F2.3S peptides.
Physicochemical Properties Peptides
BF2 F2.3S
Theoretical mass (Da) 2434 1570
Experimental mass (Da) 1 2434.88 1575.93
Net charge +6 +1
Isoelectric point 12.44 9.07
GRAVY −0.63 1.17
Hydrophobic ratio 33% 47%
W-W Hydrophobicity 2 (Kcal/mol) 7.73 5.55
Boman index (Kcal/mol) 3.34 −1.66
Stability Unstable Stable
Half-life in vitro (Mammalian reticulocytes) 3 7.2 h 30 h
Half-life in vivo (Yeast) 3 >20 h >10 h
Half-life in vivo (E. coli) 3 >20 h >10 h
1 Average experimental mass of synthetic peptides (see Figure S4 for HPLC chromatograms and MS spectra).
2 Octanol-Interface scale. 3 Calculated using the APD server.
Int. J. Mol. Sci. 2018, 19, 2170 5 of 21
The positive net charge and the amphipathic composition of the peptides confirm their potentiality
for presenting antimicrobial activity. The peptide physicochemical properties are also in agreement
with their capacity to interact with the anionic membranes of bacterial cells. On the other hand,
some of the calculated ranks predict a differentiated behavior between the two studied peptides.
A higher positive net charge is shown for BF2 in relation to F2.3S, which might explain its stronger
binding affinity to nucleic acids. The hydropathicity index (GRAVY) and the W-W Hydrophobicity
indicated that F2.3S might have a higher tendency to bind and cross lipid bilayers, whereas the
Boman Index showed that BF2 has a higher affinity to proteins. Furthermore, the predicted stability
of the peptides and calculated half-life using the APD database tool (APD, available online: http:
//aps.unmc.edu/AP/) suggested that the in vitro half-life and stability were higher for F2.3S than
BF2, although the half-life in vivo prediction was similar for the two peptides.
2.2. Antibacterial and Cytotoxic Activities of BF2 and F2.3S Peptides
The peptides antibacterial activities were assessed establishing their minimum bactericidal
concentrations (MBC100) and their 50% effective dose (ED50) using representative Gram-positive
and Gram-negative bacteria: Staphylococcus aureus (ATCC502A) together with three clinical isolates,
Escherichia coli (BL21) and two reference strains of Pseudomonas aeruginosa (PA01, PA14) together
with two clinical isolates (see resistance profiles of clinical isolates in Table S1). The values obtained
are shown in Table 2. Both peptides were effective against S. aureus and E. coli at low micromolar
concentration. Nonetheless, both peptides inhibited E. coli growth at a lower concentration than that
of S. aureus. Particularly, the ED50 for the F2.3S peptide against E. coli (0.23 ± 0.01) was five-fold lower
than the required for S. aureus. On the other hand, the concentrations to inhibit the two tested reference
strains of P. aeruguinosa were slightly higher than the ones required for E. coli. To note, the peptides’
efficiency against the selected clinical isolates (Table S1) was mostly reduced, in particular for BF2,
which could not reach a 50% inhibitory concentration even at 100 µM (Table 2).
Taking into account that one of the major concerns for the use of peptides in systemic treatments
is their toxicities, we evaluated the effect of both peptides against erythrocytes and primary human
monocytes. The results showed that neither BF2 nor F2.3S were toxic to primary human monocytes
even at a 100-fold higher concentration than their calculated antimicrobial ED50 (Table 2). In regard to
the hemolytic activity, BF2 showed a less hemolytic effect than F2.3S. Furthermore, none of the two
peptides reached a 50% hemolysis when tested up to 200 µM final concentration (Figure 3).
Table 2. Antimicrobial and cytotoxic activities of BF2 and F2.3S peptides.
Biological Activity Peptide
BF2 F2.3S
Gram negative MBC100 (µM) 0.93 0.62
E. coli (BL21) ED50 (µM) 0.33 ± 0.005 0.23 ± 0.01
ED50 (µM) 1.3 ± 0.082 3.4 ± 0.062
P. aeruginosa (PA01) ED50 (µM) 1.8 ± 0.005 3.1 ± 0.003
P. aeruginosa (PA14) ED50 (µM) >100 >100
P. aeruginosa (M8C1) * ED50 (µM) >100 >100
P. aeruginosa (M18C1) *
Gram positive MBC100 (µM) 1.87 1.87
S. aureus (ATCC 502A) ED50 (µM) 0.51 ± 0.02 1.1 ± 0.07
ED50 (µM) 6.46 ± 0.002 11.99 ± 0.001
S. aureus (39413) * ED50 (µM) >100 55.82 ± 0.005
S. aureus (34026) * ED50 (µM) >100 >100
S. aureus (36055) *
Human monocytes CC50 (µM) >100 >100
* Clinical isolates: the antibiotic resistance profile is detailed in Table S1.
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Minimum Bactericidal Concentrations (MBC100) were determined by CFU counting following
plating of bacterial culture onto Petri dishes after four hours of incubation with serial peptide
concentrations. The ED50 was calculated by ATP quantification using the BacTiter-Glo™ Microbial Cell
Viability kit (Promega, Madison, WI, USA). Cell cytotoxicity was quantified using resazurin reduction
in human monocytes. Fifty percent cytotoxic concentration (CC50) was calculated as described in
Materials and methods. Data averaged from three replicates of two independent experiments. Values
are given as mean ± SEM.
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2.3. Bacterial Membrane Depolarization, Permeabilization and Agglutination Activities of BF2 and
F2.3S Peptides
To characterize the antimicrobial mechanism of action by the two amphibian peptides,
we evaluated their abilities to depolarize and permeabilize E. coli bacterial cytoplasmic membranes.
Depolarization of the cytoplasmic bacterial membrane was evaluated by using the DiSC3(5) cationic
membrane-permeable fluorescent dye. The dye loses fluorescence intensity in polarized membranes
and becomes highly fluorescent upon membrane depolarization. The assay can detect changes in
membrane ion permeability or the transmembrane potential dissipation due to a pore formation
process [28]. Depolarization and leakage activity results revealed different patterns, when BF2 or
F2.3S were tested. Results indicated that BF2 antibacterial action is accomplished without requiring
a membrane permeabilization event [6,29]. No depolarization activity is observed even at 10-fold the
effective dose for bactericidal activity. Moreover, the 50% cytoplasmic membrane leakage in E. coli
is only achieved at a three-fold higher concentration than the ED50 value for its antibacterial activity
(Tables 2 and 3). In contrast, F2.3S displayed depolarization and bacterial cell leakage at lower peptide
concentrations than the effective dose for E. coli antibacterial activity (Table 3). These finding can be
related to an early membrane permeabilization and rapid leakage event process as part of the frenatin
antimicrobial mechanism of action.
Moreover, in order to further characterize the mechanism of action of both BF2 and F2.3S
peptides, we evaluated their potential capacity to agglutinate E. coli cells and calculated their minimum
agglutination concentration (MAC). Hence, for the first time, we found that BF2 has the ability to
agglutinate E. coli. Interestingly, the agglutination ability of the peptide is only effective at a higher
concentration than the one required for leakage (Table 3). On the contrary, F2.3S did not have the
capacity to produce agglutination in E. coli even at the maximum concentration tested (5 µM).
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Table 3. Depolarization, leakage and agglutination activities toward E. coli cells and/or
DOPC/DOPG liposomes.
Biological Activity Peptide
BF2 F2.3S
Depolarization (ED50) (µM) Bacteria >5 0.1 ± 0.05
Leakage (ED50) (µM) Bacteria 0.9 ± 0.1 0.1 ± 0.07
Liposomes >2 0.1
Agglutination (MAC) (µM) Bacteria 1.5 >5
Liposomes 0.5 ± 0.002 >2
The peptide concentration required to achieve half of total membrane depolarization and leakage were estimated
as effective dose values (ED50) using the membrane-potential-sensitive DiSC3 dye and SYTOX Green assays
respectively. Minimum agglutination values (MAC) were calculated as described in the methodology. Values are
given as mean ± SEM calculated from three replicates of two independent experiments.
2.4. Leakage and Agglutination Activities on Phospholipid Liposomes by BF2 and F2.3S Peptides
After defining the peptide antibacterial activity on E. coli cells, we further characterized their
mechanism of action on model membranes. Large unilamellar vesicles (LUVs) were prepared using
a mixture of neutral/anionic phospholipids (DOPC:DOPG). Liposome leakage assays were carried
out to evaluate the membrane disruption capacity of the peptides. Activity was monitored by tracing
the increase of ANTS/DPX fluorescence, after mixing the loaded liposomes with the given peptide
(Table 3). Results highlighted the different mechanism of action of both peptides. Whereas BF2 could
not trigger the vesicle leakage at its antimicrobial effective dose, F2.3S was able to release the LUVs
content at the same concentration range required for its antimicrobial activity. In addition, liposome
agglutination was determined by dynamic light scattering (DLS). Changes of the liposome population
were monitored upon interaction with BF2 and F2.3S. The results showed that BF2 promoted the
agglutination of the lipid vesicles, whereas F2.3S was not able to agglutinate them. These results
reproduced the peptides’ observed pattern on E. coli cultures.
2.5. Internalization into Bacterial Cells and In Vitro DNA Interaction by BF2 and F2.3S Peptides
Following this, in order to further explore the diverse antibacterial mechanism of actions of BF2
and F2.3S peptides, we determined the peptide bacterial cell internalization activities. We performed
FACS analysis in order to analyze the internalization of the FITC labeled peptides into E. coli
and S. aureus cells. The results showed the cell distribution before and after peptides incubation.
A fluorescence displacement confirmed the internalization within bacterial cells of both BF2 and F2.3S
labeled probes at sublethal concentrations after 10 min of incubation (Figure S2). After corroborating
the internalization of the peptides, the labeled peptide distribution was evaluated by FACS. Live/dead
cell population was analyzed by monitoring the influx of propidium iodide (PI) at 10 min and 4 h of
incubation. The distribution of live and dead cell subpopulations together with the labeled peptide
distribution is illustrated below (Figure 4 and Figure S3). Results confirmed the peptide uptake at
a non-lethal concentration, where the bacterial membrane integrity was not significantly compromised.
To explore potential intracellular targets of both peptides we assayed their ability to bind DNA
in vitro. DNA binding is a singular characteristic exhibited by the histone-derived antimicrobial
peptides [8]. By using a gel retardation assay, we confirmed the DNA binding activity of BF2
and demonstrated that F2.3S also displays this capacity (Figure 5). Both peptides displayed a high
DNA-binding activity. However, the F2.3S DNA retardation activity was slightly lower at the first
tested peptide/DNA ratio.
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2.6. Analysis of Bacterial Gene Expression Profile Pattern Induced by Peptide Incubation
After confirming the peptide cellular uptake, we aimed to determine the transcription patterns of
certain genes in E. coli and S. aureus cells after exposition with a sublethal concentration (0.1 µM) of
each peptide (Figure 6). Genes related to bacterial cellular response to stress and the development of
resistance mechanisms were selected to evaluate the peptide effect on bacterial cells. Ampicillin was
assayed as a positive control (results not shown). The housekeeping GAPDH gene served as a control.
The genes evaluated for E. coli were DnaK, ompC and smbA and 16S, parE and MprF for S. aureus.
The results showed that the presence of BF2 increased the gene expression of the chaperone of the
toposiomerase parE and the ribosome subunit 16S On the other hand, the expression of the porin ompC,
the SbmA transporter and the MprF lysyl transferase were downregulated after the treatment with
BF2 [30,31]. On its side, E. coli and S. aureus exposure to F2.3S induced a significantly distinct expression
pattern. F2.3S, like BF2, induced the upregulation of the chaperone DnaK and the downregulation of
the SbmA membrane transporter, a characteristic trait of cell stress inducers. However, F2.3S did not
induce significant changes in 16S, MprF and parE expression levels.
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Beside , in this work we have characterized for the first time a novel frenatin peptide (F2.3S) that was
recently discovered in SMOs of S. lacteus in our laborat ry [19].
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We have characterized here both BF2 and F2.3S on Gram-negative and Gram-positive cell cultures
and model membranes. The two AMPs expressed in SMOs of S. lacteus [19,25] are endowed with
cationic and amphipathic properties (Table 1). In silico AMPs’ physicochemical analysis is considered
as an important predictor to define their antibacterial potency and putative mechanism of action.
In accordance with the in silico results, the higher net charge of BF2 (+6) in comparison with F2.3S (+1),
leads to an enhanced electrostatic interaction between the peptide and bacterial anionic membranes [32–
34]. This is considered the first step to initiate the translocation of peptides across the bacterial
membrane [12]. Moreover, the in silico predicted results suggest that BF2 may have a high affinity to
other proteins, as indicated by its Boman index (Table 1). This could indicate, that in vivo this peptide
can form complex associations with other peptides to enhance its activity and stabilize its structure [32].
This result might be concomitant to the predicted stability of BF2 in vivo, in contrast to the short
half-life calculated for in vitro conditions. On the other hand, F2.3S in silico predictions indicate its
tendency to interact with membranes, based on the W-W interfacial hydrophobicity scale and the high
hydrophobicity ratio (47%) (Table 1). This result agrees with the well-established correlation between
the high hydrophobicity of many AMPs and their capacity to disturb membranes [33]. In addition,
a common feature observed in membrane-active peptides is their capability to directly disturb the
bilayer integrity, either by the creation of local damage, massive disruption or pore formation [32,34].
In contrast to BF2, a higher in vitro stability is predicted for F2.3S.
Following, the two peptide activities were evaluated on Gram-negative and Gram-positive
species. BF2 inhibited the growth of both Gram-negative and Gram-positive bacteria at remarkably
low micromolar concentrations (Table 2). As reported previously for BF2 peptides purified from other
species [9–14], our results highlight the BF2 elevated bactericidal activity. In regard to F2.3S and
as predicted by in silico analysis, this peptide also presented a potent antibacterial activity against
both E. coli and S. aureus reference cultures (Table 2). Moreover, along with their high and potential
spectrum antibacterial capability, the new molecules must comply a low toxicity for human cells before
considering their medical use [1]. Our findings discard any significant toxicity of BF2 and F2.3S on
human primary monocytes at the highest tested concentration. In addition, the hemolysis rate of both
peptides was lower than 50% (Figure 3) at more than 50-fold concentration its antimicrobial ED50,
ensuring a suitable therapeutic index. Notwithstanding, F2.3 shows a comparatively higher hemolysis
rate in comparison to BF2. This difference might probably be due to the high hydrophobicity of F2.3S
peptide versus BF2, as observed for other peptides [35].
AMPs have different strategies to carry out a rapid and effective removal of microbial
infection. Among the major biophysical indicators of AMPs mechanism of action we find membrane
depolarization and leakage, as well as cellular agglutination, cellular internalization and nucleic acid
binding [4,36,37]. In this study, first we evaluated the membrane depolarization and permeabilization
capacity of both peptides in E. coli cultures. As previously reported, BF2 is able to enter into the
cytoplasmic membrane without generating significant depolarization and/or cellular leakage (Table 3).
This pattern is consistent with the currently accepted mechanism of BF2 action that establishes its
ability to translocate into bacteria without disrupting the membrane [9–14]. Our findings unveil
for the first time the capacity of BF2 to agglutinate E. coli cells and liposomes when increasing the
peptide concentration above its effective antimicrobial concentration. The result for BF2 is in agreement
with other reports that highlight the importance of electrostatic interaction as a part of the peptides
aggregation mechanism of action [34,38]. Interestingly, it is frequently observed that the aggregation
activity does not participate in the initial stage of the antimicrobial mechanism, as reported for example
for the Dermaseptin S9 peptide or the human secretory RNase derived peptides [39,40]. This agrees
with our findings that show that the BF2 concentrations at which the cellular aggregation takes
place are well above its ED50 value. Nonetheless, we conceive that the BF2 cellular agglutination
activity is indeed part of its mechanism of action. Some agglutinating peptides can contribute to
prevent the spread of infection by facilitating the phagocytosis of bacteria clumps [41]. In addition,
BF2 promotion of cell agglutination might be enhanced by its union by electrostatic interactions to the
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lipopolysaccharides (LPSs) at the outer membrane of Gram-negative bacteria and reduce the endotoxin
circulating free levels, as reported for other AMPs [42–45].
On the other hand, we report here for the first time the antibacterial mechanism of F2.3S.
The peptide has a membrane destabilization mechanism that involves the rapid depolarization of
the membrane and its further destabilization. On the contrary, the agglutination activity of BF2 is
not shared by F2.3S. In any case, both peptides can translocate into the cytosol and interact with
nucleic acids. Cell internalization and DNA binding assays were performed taking into account the
previously described BF2 capacity to penetrate membranes without lysing bacteria. Once inside,
BF2 bounds tightly to nucleic acids, inhibiting macromolecular processes of the cell [46]. Interestingly,
our results showed that F2.3S is also able to inhibit the migration of DNA in a gel electrophoresis
assay, although this activity was only evidenced when doubling the peptide/DNA ratio respect to
BF2 (Figure 5). The lower positive net charge observed for F2.3S in relation to BF2 could explain the
observed difference. To note, a prediction model of buforin interaction with DNA indicates a merely
electrostatic interaction associated to the Arg content and discards any base specific binding mode [47].
In addition, we confirmed the cellular uptake of both peptides at sub-lethal concentrations. The flow
cytometry results corroborate that BF2 is translocated into the bacterial cytoplasm. The process was
also observed for F2.3S, showing even a higher percentage of the cell population that incorporated the
labeled peptide, in comparison to the treated cells with BF2 (Figure 4). Therefore, F2.3S at sublethal
concentrations could be internalized and can target intracellular molecules such as DNA.
Following, we evaluated the putative intracellular effect of BF2 and F2.3S in E. coli and S. aureus
by monitoring the expression pattern of selected genes related to bacterial stress conditions. The results
showed that in E. coli, the DnaK gene was upregulated after the exposition of the cells to BF2 and
F2.3S, as observed for the ampicillin positive control. This finding demonstrates that BF2 and F2.3S
at a membrane non-lytic concentration alter the bacterial cell gene expression profile. Interestingly,
DnaK is one of the most abundant constitutively expressed and stress-inducible chaperones in the
E. coli cytosol but it is not essential under non-stress conditions [48]. Conversely, the porin ompC gene
was downregulated by BF2 and upregulated by F2.3S. According to the bibliography, the E. coli ompC
gene expression is usually altered in response to different antibiotics exposure [49,50]. We find in
the literature, together with other cell penetrating peptides, reports of BF2 exerting its antimicrobial
action by interfering with key cellular roles, such as cell wall synthesis and protein-folding assisted
by chaperones [51]. Similarly to BF2, other studies have reported that E. coli exposed to the AMPs,
such as Esculetin, diminished the expression of the ompC gene [51]. In regard to the sbmA gene of
E. coli, we observe a mild reduction of its expression in the presence of both peptides, as observed
for the ampicillin positive control. This gene encodes a transmembrane protein transporter [52].
The downregulation of the SbmA can block the transport of antibiotics into the cell cytoplasm and
can represent a bacterial resistance mechanism. To note, the bacterial downregulation of ompC and
SbmA genes that are related to peptide uptake might represent a mechanism of protection against
AMPs [49,53]. For example, mutant strains lacking the OmpC porin acquired antibiotic resistance [54].
Significant changes in the gene expression pattern in S. aureus, after exposition with BF2 and F2.3S,
were also registered. Specifically, the expression of the 16S and parE genes was upregulated in the
presence of BF2, whereas the expression of the MprF gene was only slightly altered for the treated
cells with both peptides. We hypothesize that transcription upregulation of 16S and the topoisomerase
parE upon bacterial incubation with BF2 can constitute an adaptation response mechanism to the
peptide binding to nucleic acids. On the other hand, modulation of the MprF gene, involved in the
synthesis of the bacterial wall exposed positively charged LPG has been related to bacterial evasion of
cationic peptides action [55,56]. However, the present results suggest that the assayed conditions were
not sufficient to induce a significant bacterial response to BF2 and F2.3S exposure. Overall, our data
reveal for the first time the ability of BF2 and F2.3 peptides to induce the bacterial stress response
and alter specific genes involved in bacterial resistance mechanisms [57]. We can conclude that BF2
exposure mostly shows a prominent shift of the bacteria gene transcription profile pattern associated
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to cellular stress, e.g., increase expression of DnaK chaperone, parE DNA topoisomerase IV and 16S
rRNA. On the other hand, the gene expression pattern is less altered by F2.3S exposure. However,
the increase of DnaK following F2.3S exposure indicates to some extent the activation of bacterial
cellular stress processes. The reduced response related to bacterial resistance markers observed for
F2.3S might be explained by its different mechanism of action. The higher antimicrobial activity and
more prominent membrane destabilization activity of F2.3S might impede the emergence of bacterial
response processes.
Overall our results suggest that BF2 and F2.3S identified in SMOs of S. lacteus can exert diverse
bacteria killing strategies at an effective concentration range that is potentially non-toxic to human
host cells. We have confirmed that BF2 mechanism of action involves translocation and intracellular
targets. In this regard, we evidenced that BF2 altered the expression of key survival genes from the
bacteria. In addition, we found that bacterial agglutination can also participate in the BF2 action against
Gram-negative bacteria. We hypothesize that this mechanism can facilitate the bacteria removal from
the infection focus and might reduce the LPS blood circulating levels and thereby have beneficial
anti-endotoxin properties. On the other hand, F2.3S can also achieve its translocation into bacterial
cells at sublethal concentrations, and shows an even higher antimicrobial activity in comparison to
BF2. The results suggest that F2.3S can combine its membrane destabilizing action together with
an intracellular targeting of key cellular functions. Thereby, both frog AMPs can undertake distinct
mechanisms of action dependent on their relative effective concentration [34,58–61]. Therefore, the two
peptides purified from S. lacteus constitute another example of secreted AMP with multifunctional
mode of action [56,59,62]. The present work corroborates that frog skin secretory micro-organs
represent a continuing source of novel peptides with multifaceted mechanisms of action. Taking into
consideration that SMOs mimic an open injured tissue [63], we are confident that frog secreted AMPs
would be regarded as attractive lead molecules to develop novel antibiotic therapies. Indeed, the first
AMP selected for Phase III clinical trials to treat wound injuries, Pexiganan, is a short synthetic analogue
of magainin, an AMP secreted by the frog Xenopus laevis [64]. Moreover, recent in vivo studies in mice
models confirmed the wound healing properties of frog AMPs [65]. We propose here BF2 and F2.3S as
potential lead candidates to assist in the design of novel antimicrobial agents against superbugs that
have developed multiple strategies of resistance.
4. Materials and Methods
4.1. In Silico Analysis
In silico analysis of the BF2 and F2.3S general peptide characteristics, stability related features,
sequence similarities with other related peptides, as well as the stability in vitro and in vivo were
analyzed with a broad repertoire of databases and bioinformatics tools. Using HELIQUEST the alpha
helix conformation and the physicochemical properties of these peptides was explored. The “APD3:
Antimicrobial Peptide Calculator and Predictor” tool of the Antimicrobial Peptide Database (APD) [26]
was used to identify the following general characteristics of antimicrobial peptides: net charge,
hydrophobic and hydropathy (GRAVY) ratio, potential capacity to attach to other proteins (Boman
Index), alpha helices structuration or sequence specific amino-acids enrichment (Table 1). The Membrane
Protein Explorer (MPEx) allowed us to determine the potential of the peptides to bind to membrane
bilayers [66]. The ProtParam Tool was used to identify the stability features of the two peptides, allowing
recognition of their suitability to remain stable in specific environments [67]. Based on the N-terminal
amino acid of each peptide, the half-life in vitro and in vivo was predicted along with the aliphatic
index and classification of the stability of the peptide. Likewise, the “HLP: Web server for predicting
half-life of peptides in intestine-like environment” permitted the prediction of the half-life and stability
of the new peptides in an intestine-like, proteolytic environment [68].
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4.2. Peptide Synthesis
Previous work from our laboratory identified precursors from BF2 and F2.3S secreted by
S. lacteus skin micro-organs [19,25]. Based on those sequences we synthesized and purified BF2
(TRSSRAGLQFPVGRVHRLLRK) and F2.3S (GLVGTLLGHIGKAILGG) (Accession no.AGB51284.1).
The peptide synthesis was performed by GL Biochem Shanghai (Shanghai, China) and the Peptide
Synthesis Facility at Proteomic Unit, Prof. David Andreu laboratory, Universitat Pompeu Fabra (UPF),
Spain. Purification was performed by HPLC (>95%) on a Vydac C18 (2.2 cm × 25 cm) and Luna
C18 (4.6 × 50 cm) columns. The unlabeled and FITC-labeled peptides were purified by Luna C18
with a linear gradient of 0.036% TFA in MeCN into 0.045% TFA in H2O at a flow rate 1 mL/min.
The peptide masses were confirmed by liquid chromatograph-mass spectrometry (LC-MS) using
a 2010EV Shimadzu instrument (Kyoto, Japan). Purification profiles and MS spectra are shown in
Figure S4.
4.3. Minimum Bactericidal Concentration
Antimicrobial activity was calculated as the 100% minimum bactericidal concentration (MBC100),
defined as the lowest peptide concentration that completely eradicated microbial growth. The MBC
of each peptide was determined as described previously [69,70]. Bacteria were incubated at 37 ◦C
overnight in Luria-Bertani broth (LB) and diluted to approximately 5 × 105 CFU/mL. The strains used
in this study corresponded to Escherichia coli BL21 from Novagen (Madison, WI, USA), Staphylococcus
aureus (ATCC502A) obtained from the Colección Española de Cultivos tipo (CECT), Universidad de
Valencia, Spain, Pseudomonas aeruginosa (ATCC® 15692, PAO1), from the American Type Culture
Collection (ATCC; Rockville, MD, USA) and P. aeruginosa PA14 were used as reference strains. Three
clinical isolates of S. aureus, MRSA (34026, 36055 and 39413) and two clinical isolates of P. aeruginosa
(M8C1 and M18C1) were obtained by the kind donation of the Centro de Investigaciones Microbiológicas,
CIMIC (Universidad de los Andes, Bogotá, Colombia). In each assay, peptides were serially diluted
from 20 to 0.1 µM final concentration in Hepes 20 mM, 0.1 M NaCl, pH 7.5 buffer and added to 100 µL
aliquots of the bacterial dilution and incubated for 4 h at 37 ◦C. Subsequently, samples were plated
onto Petri dishes and incubated at 37 ◦C overnight. MBC values were determined as a function of the
total removal of CFU by the peptide from two independent experiments performed in triplicate.
4.4. Cell Viability Assay by ATP Quantification
Antibacterial activity was assayed by following the cell viability of E. coli and S. aureus, using the
BacTiter-Glo™ Microbial Cell Viability kit (Promega), which measures the number of viable bacterial
cells, by ATP quantification. ATP, as an indicator of metabolically active cells, is indirectly measured
by a coupled luminescence detection assay. The luminescent signal is proportional to the amount of
ATP required for the conversion of luciferin into oxyluciferin in the presence of luciferase. Briefly,
an overnight culture of E. coli was inoculated in a fresh LB to reach logarithmic phase OD600 of 0.2,
washed and resuspended in Hepes 20 mM pH 7.5, 0.1 M NaCl. Peptide concentration was assayed from
100 to 0.1 µM. E. coli viability was followed after 4 h of incubation at 37 ◦C. 50 µL of incubation culture
were mixed with 50 µL of BacTiter-Glo™ reagent in a microtiter plate following the manufacturer
instructions and incubated at room temperature for 10 min. Luminescence was read on a Victor3 plate
reader (PerkinElmer, Waltham, MA, USA) with a 1-s integration time. Fifty percent effective dose
concentrations (ED50) were calculated by fitting the data to a dose–response curve with Prism6®.
4.5. Hemolysis Assay
The hemolytic activity of the peptides was determined by a previous method [71]. Briefly,
2 × 107 erythrocytes from healthy human blood were washed three times with 150 mM of NaCl
and then replaced with 1 mL of PBS at pH 7.4. Serially diluted concentrations of BF2 and F2.3S were
prepared up to a maximum final concentration of 200 µM. The hemolytic assay was performed in
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flat-bottomed 96-well microtiter trays, 10 µL of each peptide concentration and 190 µL of the diluted
red blood cells were incubated for 1 h at 37 ◦C. After incubation, the assay was centrifuged and
the absorbance (450 nm) of each resuspended pellet was measured on a microplate absorbance
spectrophotometer (Bio-Rad, Philadelphia, PA, USA). The positive control was an erythrocyte
suspension incubated in 10% of Triton (100% hemolysis), and the negative control was an erythrocyte
suspension incubated in PBS 1× (0% hemolysis).
4.6. Cytotoxicity Assay in Human Monocytes
Human monocytes were isolated from peripheral human blood by Ficoll–Hypaque density
gradient (Sigma Chemical Co., St. Louis, MO, USA). The buffy coats were washed with 5 mL of saline
solution, pH 7.5 and placed in Petri dishes with RPMI 1640 medium (Gibco BRL-life Technologies
Inc., Grand Island, NY, USA), 5% fetal bovine serum (Microgen, Bogotá, Colombia), and after 24 h
incubation at 37 ◦C the adherent cells were recovered using a scraper. The cell viability was determined
using trypan blue. Human monocytes (4 × 105 cells/well) and BF2 and F2.3S peptides serially diluted
up to 100 µM were cultured in 96 well plates for 72 h at 37 ◦C. Finally, the resazurin reduction assay was
used to evaluate the cytotoxicity of these peptides at 595 nm. Addition of resazurin (Sigma-Aldrich,
St. Louis, MO, USA) was added at 44 µM final concentration. The cytotoxic concentration 50, CC50,
was taken as the mean concentration of peptide producing 50% cell death in two independent
experiments and was calculated by non-linear regression analysis using GraphPad Prism software
version 6.0 (GraphPad Software, San Diego, CA, USA).
4.7. Bacterial Cell Membrane Depolarization Assay
Membrane depolarization was assayed by monitoring the DiSC3(5) fluorescence intensity in
response to changes in transmembrane potential as described previously [72]. E. coli cells were grown
at 37 ◦C to the mid-exponential phase and resuspended in 5 mM Hepes-KOH, 20 mM glucose and
100 mM KCl at pH 7.2 until OD600 of 0.05 was reached. DiSC3(5) was added to a final concentration
of 0.4 µM. Changes in the fluorescence for alteration of the cytoplasmic membrane potential were
continuously monitored at 20 ◦C at an excitation wavelength of 620 nm and an emission wavelength
of 670 nm. When the dye uptake was maximal, as indicated by a stable reduction in the fluorescence
as a result of quenching of the accumulated dye within the membrane, the protein diluted in 5 mM
Hepes-KOH buffer at pH 7.2 was added at a final peptide concentration from 0.1 to 5 µM. All conditions
were assayed in duplicate. The time required to reach a stabilized maximum fluorescence reading was
recorded for each condition, and the time required to achieve half of total membrane depolarization
was estimated as effective dose values (ED50).
4.8. Bacterial Cell Leakage Assay
Bacterial cell leakage was evaluated using the SYTOX Green assay. E. coli cultures were grown to
mid-exponential growth phase (OD600 ~0.2) in LB medium and then centrifuged (5000× g for 2 min at
25 ◦C), washed and resuspended in phosphate buffer. Cell suspensions for OD600 ~0.05 were incubated
with 5 µM SYTOX Green (Invitrogen, Carlsbad, CA, USA) during 15 min in the dark before the influx
assay. At 2–4 min after initiating data collection peptide concentrations from 0.625 to 5 µM were added
to the cell suspension, and the increase in SYTOX Green fluorescence was measured (485 and 520 nm
excitation and emission wavelengths respectively) for 40 min in a Cary Eclipse spectrofluorimeter,
Agilent Technologies, Madrid, Spain. Maximum fluorescence was that resulting from cell lysis with
TritonTM X-100 (Sigma-Aldrich).
4.9. Minimum Agglutination Concentration (MAC)
For determination of minimum agglutination concentration (MAC) values, bacterial cells
were grown at 37 ◦C to mid-exponential phase (OD600 = 0.6), centrifuged at 5000× g for 2 min,
and resuspended in Tris-HCl buffer, 0.1 M NaCl, pH 7.5 to give an absorbance of 0.2 at 600 nm.
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A 100 µL aliquot of the bacterial suspension was incubated with the peptide at various (0.01–10 µM)
concentrations at 37 ◦C for 1 h. Agglutination behavior was observed by visual inspection using
a 50× stereoscope microscope and the MAC value was expressed as described [45].
4.10. Large Unilamellar Vesicle (LUV) Liposome Preparation
LUVs containing DOPC/DOPG (3:2 molar ratio) of a defined size (approximately 100 nm) were
prepared as described previously [73]. LUVs were obtained from a vacuum-drying lipid chloroform
solution by extrusion through 100 nm polycarbonate membranes. The lipid suspension was frozen
and thawed ten times before extrusion. A 1 mM stock solution of liposome suspension in 10 mM
phosphate buffer and 100 mM NaCl (pH 7.4) was prepared.
4.11. Liposome Membrane Leakage Activity
Membrane leakage activity was assessed by ANTS/DPX (8-aminonaphthalene-1,3,6-trisulfonic
acid disodium salt/p-xylenebispyridinium bromide) as previously [74]. Large unilamellar vesicles
of dioleoylphosphatidylcholine: dioleoylphosphatidylglycerol (3:2 molar ratio), containing 12.5 mM
ANTS and 45 mM DPX in 20 mM NaCl, 10 mM Tris/HCl, pH 7.5 were prepared. The ANTS/DPX
liposome stock suspension was diluted to 30 µM and incubated at 37 ◦C with protein/peptide, serially
diluted from 20 µM to 0.1 µM in a microtiter plate. Fluorescence measurements were performed on
a Victor3 plate reader (PerkinElmer, Waltham, MA, USA). ED50 values were calculated by fitting the
data to a dose–response curve with Prism6®.
4.12. Dynamic Light Scattering (DLS)
Liposome agglutination was analyzed by DLS (dynamic light scattering) using a Malvern
4700 photon correlation spectrometer (Malvern Instruments, Malvern, UK). An argon laser (λ = 488 nm)
was used to cover the wide size range involved. Hydrodynamic radius measurements were always
carried out at a reading scattering angle of 90◦. From the intensity measurements recorded, data were
processed by the CONTIN software (Malvern), and the hydrodynamic diameter, the polydispersity
index and the total number of counts were calculated. The incubation buffer was 10 mM Tris/HCl and
100 mM NaCl (pH 7.4). Measurements were performed at 25 ◦C, at 30 µM final liposome concentration
and 0.1–2 µM BF2 and F2.3S peptide concentrations.
4.13. Fluorescence-Activated Cell Sorter (FACS) Assay
Bacterial cell overnight culture was inoculated in a fresh LB to reach logarithmic phase OD600
of 0.2. A 500 µL aliquot of the bacterial suspension was incubated with 0.5 µM of each peptide for
10 min. After incubation and subsequently washes with 1× PBS at least thrice to remove presence of
FITC-labeled peptide in the medium, 20,000 cells were subjected to FACS analysis using a FACSCalibur
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The peptide bacterial uptake was assayed
using 0.10 µM and 0.5 µM of each peptide at the first 10 min and after 4 h of peptide incubation.
The histogram represents the peptide fluorescence into the bacterial cells (X axis) and cellular count
(Y axis). The influx of propidium iodide (PI), a DNA-staining fluorescent probe, and FITC-labeled
peptides BF2 and F2.3S into bacterial cells (E. coli and S. aureus) was investigated by using a dual laser
fluorescence- activated cell sorter and represented by percentage of cell distribution using R software
R (Foundation for Statistical Computing, Vienna, AT, USA) [75].
4.14. DNA Binding Assay
The binding of peptides to DNA was examined by a gel retardation assay as described
previously [7,10]. Briefly, 200 ng of pET28 plasmid DNA was incubated with increasing concentrations
of BF2 and F2.3S in 20 µL of binding buffer (5% glycerol, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA,
1 mM DTT, 20 mM KCl and 50 ng/mL BSA) at room temperature for 20 min and subjected to
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electrophoresis on a 1.0% agarose gel. DNA bands were visualized by ethidium bromide staining.
The peptide-to-DNA weight ratios were 0:1, 2.5:1, 5:1 and 10:1 respectively. The running conditions
were established according to [76].
4.15. Gene Expression Analysis
The bacterial gene expression of proteins implicated in stress pathways and bacterial resistance
response was evaluated following incubation with sub-lethal concentrations of the peptides.
The following genes were selected: DnaK gene encoding for a chaperone, ompC gene encoding
for a protein porin; sbmA encoding for an integral inner membrane protein that participates in an
ABC transporter, parE encoding for a DNA topoisomerase IV and MprF for a lysyl transferase that
ensures the synthesis of lysylphosphatidylglycerol (LPG). Total bacterial RNA was extracted using the
mirVAna™ Isolation Kit, which integrates an organic extraction and solid-phase extraction to obtain
high yields of ultra-pure, high quality RNA. Bacterial cells culture (1.5 mL) at log-phase (OD600 of 0.2)
were incubated using 0.1 µM of BF2 and F2.3S peptides during 30 min. Ampicillin was used at the
same concentration as a positive control. After incubation cells were sedimented and resuspended in
lysis buffer. RNA isolation was done according to manufacturer’s instructions. The amount of RNA
extracted was quantified using Quantus™ Fluorometer (Promega). Approximately 150 ng/µL was
obtained per culture sample. Complementary DNA (cDNA) synthesis is the first step of the two-step
quantitative reverse transcriptase Polymerase Chain Reaction (RT-qPCR). cDNA was generated by the
enzyme reverse transcriptase (RT). An aliquot of 1000 ng of total RNA was used to synthesize cDNA
according to the manufacture instruction of iScript™ cDNA Synthesis Kit.
4.16. Real Time Quantitative PCR Polymerase Chain Reaction (RT-qPCR)
Gene expression of Escherichia coli and Staphylococcus aureus after peptide incubation was
determined by Real Time Quantitative Polymerase Chain Reaction (RT-qPCR). The amount of amplified
product was measured at each PCR cycle by using fluorescent probes and reading the signal emitted
from the dyes while performing the thermal cycling. 1 µL of cDNA (5 ng) was mixed with 2 µL
of RNase free water, 5 µL of iTaq Universal Master SYBR green Supermix, 1 µL of each primer of
interest (500 nM), for a total volume of 10 µL per reaction. The genes studied in E. coli cells correspond
to DnaK, ompC, SbmA and 16S MprF, parE for S. aureus. GAPDH was used as housekeeping for
date normalization in the qPCR assays. Gene expression level was analyzed using a comparative
quantification method ∆Cq. This method assesses the fold change compared to a calibrator sample
(control or group of reference). Counts for genes of interest were adjusted in relation to a reference
(housekeeper) gene GAPDH. Reactions were subjected to 60 ◦C for 1 min and 95 ◦C for 10 min,
followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. Each sample was analyzed in triplicate.
Data analysis was performed using Bio-Rad CFX Manager. The figure of gene level expression was
designed by R project [75].
4.17. Statistical Analysis
Statistical analyses were performed using Prism6® by one-way ANOVA. The results are from
three independent experiments performed on different days. A p value < 0.05 was considered
statistically significant.
5. Conclusions
Our laboratory identified for the first time the presence of buforin BF2 and frenatin F2.3S in the
skin micro-organs (SMOs) from the Orinoco lime treefrog (S. lacteus). Here, we have characterized
both antimicrobial peptide properties. Evaluation of BF2 on bacteria cultures and model membranes
confirmed its previously reported non-membranolytic mechanism of action. Following intracellular
translocation, BF2 can interact with DNA and alter the bacteria transcription profile. Complementarily,
we found for the first time that BF2 can also induce the agglutination of bacterial cells. On the other
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hand, this is the first report of F2.3S antimicrobial properties. Frenatins constitute a small peptide family
very poorly studied till now that is attracting particular interest because of its multifaceted properties.
We demonstrate here that F2.3S displays a high antimicrobial activity for both Gram-negative and
Gram-positive species. The peptide can also translocate into the bacterial cytosol, bind to nucleic acids
and induce the expression of genes related to cellular stress. Besides, F2.3S can induce membrane
depolarization and leakage but cannot trigger the bacterial cell agglutination. In summary, our study
demonstrates that the mechanism of F2.3S and BF2 identified in the SMOs of S. lacteus involves actions
both at the bacterial surface and intracellular levels, highlighting their multifunctional antimicrobial
activities. In particular, the present characterization of F2.3S unveils its appealing properties for the
design of lead drug candidates to develop alternative antibiotic agents.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/8/
2170/s1.
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APD Antimicrobial peptide databases
AMPs Antimicrobial peptides
ANTS 8-aminonaphthalene-1,3,6-trisulfonic acid
BF2 Buforin II
CFU Colony forming units
DLS Dynamic light scattering
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine
DOPG 1,2-Dioleoyl-sn-glycero-3-phosphoglycerol
DTT Dithiothreitol
ED50 50% effective dose
FACS Fluorescence-activated cell sorting
F2.3S Frenatin 2.3S
IL Interleukin
LB Luria-Bertani media
LPS Lipopolysaccharide
LUV Large unilamellar vesicle
MAC Minimum agglutination concentration
MBC Minimum bactericidal concentrations
MPEx Membrane protein explorer
SMOs Skin micro-organs
FITC Fluorescein
TNFα Tumor necrosis factor-alpha
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